Published in Br J Cancer on January 16, 2006
Cultured Circulating Tumor Cells in Prostate and Other Cancers | NCT02123862
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices (2011) 2.10
Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle (2006) 1.21
Nanowire substrate-based laser scanning cytometry for quantitation of circulating tumor cells. Nano Lett (2012) 1.19
Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine. Breast Care (Basel) (2012) 1.05
Separation of tumor cells with dielectrophoresis-based microfluidic chip. Biomicrofluidics (2013) 1.04
Microneedle Biosensor: A Method for Direct Label-free Real Time Protein Detection. Sens Actuators B Chem (2013) 1.02
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget (2015) 0.95
Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol (2013) 0.95
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer (2010) 0.93
A stochastic Markov chain model to describe lung cancer growth and metastasis. PLoS One (2012) 0.93
Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol (2012) 0.91
Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer. BMC Cancer (2006) 0.88
Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg (2011) 0.87
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J Oncol (2009) 0.87
Sorting of circulating tumor cells (MV3-melanoma) and red blood cells using non-inertial lift. Biomicrofluidics (2013) 0.86
Extended cavity laser enhanced two-photon flow cytometry. J Biomed Opt (2008) 0.83
Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR. Cancers (Basel) (2013) 0.81
Detection of tumor cell-specific mRNA in the peripheral blood of patients with breast cancer—evaluation of several markers with real-time reverse transcription-PCR. Int J Mol Sci (2013) 0.81
Simple Multi-level Microchannel Fabrication by Pseudo-Grayscale Backside Diffused Light Lithography. RSC Adv (2013) 0.80
Carcinoembryonic antigen and cytokeratin 20 in peritoneal cells of cancer patients: are we aware of what we are detecting by mRNA examination? Br J Cancer (2008) 0.79
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. J Clin Oncol (2016) 0.77
Detection of circulating tumour cells on mRNA levels with established breast cancer cell lines. Biomed Rep (2012) 0.77
The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells. Int J Mol Sci (2016) 0.76
Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A review. Clujul Med (2016) 0.75
Isolation of viable cancer cells in antibody-functionalized microfluidic devices. Biomicrofluidics (2014) 0.75
Real-Time qPCR-Based Detection of Circulating Tumor Cells from Blood Samples of Adjuvant Breast Cancer Patients: A Preliminary Study. Breast Care (Basel) (2016) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A (1998) 4.76
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res (2002) 3.54
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Cancer cells in the blood; a five to nine year follow up study. Ann Surg (1959) 2.57
Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: A preliminary report. World J Surg Oncol (2005) 1.97
Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol (2002) 1.81
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer (2005) 1.48
Circulating tumour cells in breast cancer. Lancet Oncol (2004) 1.44
Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer (1998) 1.42
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res (2002) 1.33
Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer (2003) 1.28
Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res (2000) 1.24
Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol (1998) 1.23
Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res (2001) 1.09
Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res (1999) 0.99
Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol (1999) 0.98
Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem (2004) 0.95
Unreliability of carcinoembryonic antigen (CEA) reverse transcriptase-polymerase chain reaction (RT-PCR) in detecting contaminating breast cancer cells in peripheral blood stem cells due to induction of CEA by growth factors. Bone Marrow Transplant (1999) 0.93
Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. Breast Cancer Res (2004) 0.92
Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer (2000) 0.90
Immunomagnetic tumor cell enrichment is promising in detecting circulating breast cancer cells. Oncology (2003) 0.87
CANCER CELLS IN THE PERIPHERAL BLOOD: A SECOND LOOK. Acta Cytol (1965) 0.82
Cross-reactive staining of normal bone-marrow cells by monoclonal antibody 2E11. Int J Cancer (1999) 0.80
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol (1986) 1.94
Early endoscopy. A guide to therapy for acute hemorrhage in the upper gastrointestinal tract. Arch Surg (1973) 1.77
New prognostic factors for breast cancer recurrence. Semin Oncol (2001) 1.77
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol (2000) 1.72
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol (1998) 1.59
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest (1985) 1.49
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol (1988) 1.43
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol (2001) 1.39
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther (2007) 1.39
We may be lost, but we're sure makin' good time. Cancer Invest (1993) 1.38
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med (1996) 1.27
Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res (1992) 1.14
Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol (1998) 1.09
Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol (1995) 1.07
Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun (1989) 1.05
Healing flare in skeletal metastases from breast cancer. Radiology (1994) 1.05
New agents and new medical treatments for advanced breast cancer. Semin Oncol (1987) 1.04
Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol (1997) 1.04
Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res (1986) 1.03
Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med (1996) 1.01
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther (2011) 1.00
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer (2010) 0.99
Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat (2003) 0.98
Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol (1985) 0.97
Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat (1999) 0.96
Elevated CA125 levels in patients with metastatic breast carcinoma. Br J Cancer (1990) 0.96
Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol (2013) 0.93
Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst (2000) 0.93
Adjuvant therapy for all patients with breast cancer? J Natl Cancer Inst (2001) 0.93
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol (2004) 0.90
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol (2001) 0.88
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer (2009) 0.88
Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat (1998) 0.87
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. Br J Cancer (2013) 0.87
CAF in metastatic breast cancer: standard therapy or another effective regimen? J Clin Oncol (1987) 0.86
Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys (1999) 0.86
Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat (1999) 0.86
Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol (2000) 0.83
Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res (1992) 0.83
Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res (2001) 0.83
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol (1999) 0.82
The quantitation of carbamino adduct formation of angiotensin II and bradykinin. Biophys J (1978) 0.81
Circulating tumor markers in breast cancer. Hematol Oncol Clin North Am (1989) 0.81
Adjuvant systemic therapy for patients with node-negative tumors. Cancer (1990) 0.81
Localization of tumor-associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon. Cancer (1993) 0.81
Implications for clinical management in patients with breast cancer. Long-term effects of reconstruction surgery. Cancer (1991) 0.80
High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology (Williston Park) (1997) 0.80
Ductal carcinoma in situ of the breast: a new model. J Natl Cancer Inst (1997) 0.80
Should we treat HER, too? J Clin Oncol (1996) 0.79
Comprehensive management of disseminated breast cancer. Cancer (1990) 0.79
What would you do if this were your ... wife, sister, mother, self? J Clin Oncol (1991) 0.78
Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res (1990) 0.78
The Role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer (2001) 0.78
Detection and characterization of a high molecular weight human lung carcinoma-associated glycoprotein. Cancer Res (1990) 0.78
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst (1993) 0.77
Primary radiation therapy for locally advanced breast cancer. Cancer (1987) 0.77
The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck. J Surg Oncol (1986) 0.77
Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. Clin Cancer Res (1995) 0.77
No evidence for MUC 1-induced apoptosis. Nat Med (1998) 0.77
Renal vasoconstriction in association with acute pancreatitis. Am J Surg (1974) 0.77
Closure of an aortic stump. A new method. Am J Surg (1983) 0.76
Bilateral tube thoracostomy to preclude fatal tension pneumothorax in patients with acute respiratory insufficiency. Am Surg (1976) 0.76
Clinical experience with carotid stump pressure and EEG monitoring to determine shunt placement during carotid endarterectomy. J Natl Med Assoc (1983) 0.75
Transvenous biopsy of carcinoma of bronchus causing superior vena caval obstruction. Br Med J (1975) 0.75
A "breathalyser" for lung cancer? Lancet (1999) 0.75
Fine-needle aspiration and flow cytometry for evaluation of primary breast cancer. Radiology (1992) 0.75
Doxorubicin for inflammatory breast cancer: a red humor for a red tumor? Ann Surg Oncol (1995) 0.75
Lung cancer-associated protein: development and characterization of a new assay that detects a circulating lung cancer marker. Cancer Res (1991) 0.75
Psychosocial issues in breast reconstruction. Cancer (1991) 0.75
Current recommendations on breast cancer treatment. Contemp Intern Med (1993) 0.75
Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. Cancer Res (1986) 0.75
Breast cancer screening and prevention. Contemp Intern Med (1993) 0.75
Inconstancy of "constantly" infused penicillin. JAMA (1969) 0.75
Takayasu's arteritis of the upper extremities. A case report and review of literature. Angiology (1984) 0.75
Methylation of glucagon, characterization of the sulfonium derivative, and regeneration of the native covalent structure. Biochemistry (1977) 0.75
Supradiaphragmatic right liver lobe and gallbladder. Arch Surg (1980) 0.75
Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemother Pharmacol (1999) 0.75
Effects of traumatic hypovolemic shock on renal function. J Surg Res (1974) 0.75
Diagnosis of deep venous thrombosis by phleborheographic evaluation. Nebr Med J (1983) 0.75
The use of adjuvant therapy in patients treated with conservative surgery and radiotherapy. Cancer Treat Res (1992) 0.75
Refining breast cancer risk assessment with molecular markers: the next step? J Natl Cancer Inst (1999) 0.75
Axillary lymphoscintigraphy for breast cancer: should we do it? Can we do it? J Nucl Med (1990) 0.75
Cytological changes induced by pulmonary infarction in a canine model. J Surg Res (1982) 0.75
Designing tumor marker studies: will the results provide clinically useful information. Arch Pathol Lab Med (2000) 0.75
A stepper motor controlled microdrive for recording from unanesthetized animals. Physiol Behav (1970) 0.75
Managing peripheral vascular disease secondary to arteriosclerosis. Geriatrics (1977) 0.75
Considerations in using tumor markers: what the psycho-oncologist needs to know. Psychooncology (2001) 0.75